Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Should you chase high yields from slow-growing businesses or invest in lower-yield providers with more predictable cash flows?
Lately, Pfizer (NYSE: PFE) and Prologis (NYSE: PLD) have been perfect examples of the trade-off between attractive yields and dividend growth. Pfizer offers a sky-high yield that's climbing slowly. Prologis offers a much lower yield, but it's been raising its payout at a remarkable pace.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Here's a closer look at both to help you decide which one fits your goals.
Pfizer
Shares of Pfizer have fallen about 62% from their COVID-19 pandemic highs. The stock is way down, but the company has raised its payout every year since 2009. At its beaten-down price, this stock offers an eye-popping 7.3% dividend yield.
Pfizer's COVID-19 vaccine, Comirnaty, and antiviral treatment, Paxlovid, drove adjusted earnings up to $6.58 per share in 2022. Sinking demand for COVID-19 vaccines and treatments reduced adjusted earnings to just $3.11 per share last year.
In 2025, Pfizer expects a significant earnings contraction. At the midpoint of the guided range management provided this April, adjusted earnings are expected to fall by 6.8% this year. The $2.80 per share management expects at the low end of the guided range is more than enough to support a dividend payout currently set at an annualized $1.72 annually, but there could be further contractions ahead.
Eliquis is a next-generation blood thinner that Pfizer markets in collaboration with Bristol Myers Squibb. It's currently responsible for 14% of Pfizer's total revenue and is likely to lose ground to generic competition in the lucrative U.S. market in 2028.
Long before Eliquis loses ground to generic competition, the company's lead growth driver, Vyndaquel, could stumble. BridgeBio launched a competing treatment called Attruby in late 2024, and it's been exceeding expectations.
Pfizer's facing patent cliffs, but it also has one of the most productive development pipelines in the industry. Last year alone, the Food and Drug Administration issued more than a dozen approvals to new Pfizer treatments and several that are already on the market. With plenty of new products to market, the drugmaker has a good chance to continue its payout-raising streak in the decade ahead.
Prologis
As more folks do their shopping online, demand for warehouses that can support e-commerce has soared. By anticipating the demand, Prologis has become the world's largest real estate investment trust (REIT) that everyday investors can buy shares of.
Fear and uncertainty regarding the taxes businesses need to pay when importing goods to the U.S. have pressured the stock. It's down about 12% from a peak it set in March. At its beaten-down price, it offers a 3.7% yield.
Prologis has been able to raise its dividend by 11.7% annually over the past five years. At this pace, investors who buy at recent prices could begin receiving a double-digit yield on cost in less than a decade.
Amazon, Home Depot, and FedEx are Prologis' largest customers. These three tenants are responsible for only 8.2% of the rent payments Proligis receives every month. This high level of diversification is a big reason it can boast industry-leading credit ratings.
With an A2 rating from Moody's and an A rating from S&P Global, the weighted average interest rate on Prologis' outstanding debts was just 3.1% at the end of March. Acquiring and developing properties is an important part of this REIT's business, but it also acts as a lender. With an enviable credit rating, it can produce a strong profit while offering rates that its smaller competitors can't match.
For companies that own their warehouses, selling them to Prologis and leasing them back is often their lowest-cost source of capital. With the vast majority of the world's logistics real estate still owned by the companies that use it, Prologis could continue growing at a rapid pace for decades to come.
Pfizer offers a yield that's almost twice as high as Prologis's, but the pharmaceutical giant has been raising its payout at less than half the pace of the logistics REIT. Pfizer might be a good option for folks near retirement age. For income-seeking investors, though, Prologis seems like the better dividend stock to buy now.
Should you invest $1,000 in Prologis right now?
Before you buy stock in Prologis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Prologis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!*
Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 2, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Cory Renauer has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Bristol Myers Squibb, FedEx, Home Depot, Moody's, Pfizer, Prologis, and S&P Global. The Motley Fool recommends BridgeBio Pharma and recommends the following options: long January 2026 $90 calls on Prologis. The Motley Fool has a disclosure policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
31 minutes ago
- Globe and Mail
NVDA, TSMC, AVGO: Chip Stocks Fall on Reports U.S. May Further Restrict Exports to China
Leading semiconductor stocks such as Nvidia (NVDA), Broadcom (AVGO), and Taiwan Semiconductor Manufacturing Co. (TSM) are down on June 20 as reports surface that the U.S. government may further restrict the export of microchip and semiconductor technology to China. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Specifically, the U.S. Commerce Department is considering terminating waivers that allow some chipmakers to send American technology to factories in China, including Taiwan Semiconductor that is based in the Chinese territory of Taiwan and manufactures about two-thirds of the world's microchips. Other chip and semiconductor stocks that are down on news of the potential U.S. government curbs include Qualcomm (QCOM) and Marvell Technology (MRVL). The latest move by the U.S. government comes as America and China hold a loose agreement on tariffs and an uneasy truce in their ongoing trade battle. Controls around microchips and semiconductors reportedly remain a sticking point. Digital Oil Microchips and semiconductors are often referred to as the oil of the 21st Century or digital oil. The U.S. has issued several chip export changes this year under the administration of U.S. President Donald Trump. China has called the U.S. rule changes 'discriminatory' and retaliated by restricting some critical metals and rare earth minerals. For U.S. chipmakers such as Nvidia and Broadcom, these would be the latest government curbs that could impact their global sales, limiting their ability to sell advanced artificial intelligence (AI) chips into China due to national security concerns. During its most recent earnings report, Nvidia said current export restrictions on its China-bound microchips cost the company about $8 billion in lost sales. Is NVDA Stock a Buy? The stock of Nvidia has a consensus Strong Buy rating among 40 Wall Street analysts. That rating is based on 35 Buy, four Hold, and one Sell recommendations assigned in the last three months. The average NVDA price target of $173.19 implies 19.05% upside from current levels.
Globe and Mail
an hour ago
- Globe and Mail
'A Pandora's Box': Comcast Stock (NASDAQ:CMCSA) Gains as Lawsuit Contains Serious Potential Pitfalls
The notion of artificial intelligence (AI) in the arts is as present as it is potentially calamitous. So when communications giant Comcast (CMCSA) decided to take on a comparative startup in the market it seemed like a clear response to conditions in the field. But Comcast may be letting itself in for more harm than good, a Bloomberg report noted. Despite this, shareholders are encouraged, and Comcast shares posted modest gains in Friday afternoon's trading. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Comcast, along with Disney (DIS), joined in a lawsuit targeting Midjourney, an AI company that has an image generator. And of course, a lot of AI generators turn to copyrighted materials to learn how to work. On a certain level, this is expected; let the human writer among us who was not influenced by copyrighted material—the works of another writer—throw the first stone on this one. But Comcast and Disney are going full-bore ahead with the lawsuits. And that, Bloomberg noted, is where the potential calamity lies. Disney and Comcast are presumably looking to turn to AI as well for their own projects. So while Disney and Comcast call Midjourney a 'bottomless pit of plagiarism,' they are finding themselves increasingly interested in dipping a toe in said pit, taking advantage of the staggering potential for productivity and cost savings therein. Indeed, as the Bloomberg report put it, '…when studios attempt to rein in the same technology that they're eagerly using elsewhere, the more urgent question isn't about retreat.' Independent Chair? No Way, Say Shareholders In a more mundane development, Comcast took a proposal to shareholders for an 'independent chair' of the Comcast board of directors. Such a chair, Comcast asserted, would be something of a check and balance to the power of Brian Roberts, current CEO of Comcast, who also serves as the current chair. But shareholders were happy enough with things as-is, and thus voted down the proposal. A second proposal called for consideration of 'CEO pay ratio,' or how much the CEO gets paid compared to the average employee, when considering executive pay. Shareholders apparently did not care about that either, as that proposal was likewise rejected. Is Comcast Stock a Good Buy Right Now? Turning to Wall Street, analysts have a Moderate Buy consensus rating on CMCSA stock based on nine Buys, 10 Holds and two Sells assigned in the past three months, as indicated by the graphic below. After a 10.97% loss in its share price over the past year, the average CMCSA price target of $41.44 per share implies 19.44% upside potential. See more CMCSA analyst ratings Disclosure Disclaimer & Disclosure Report an Issue
Globe and Mail
2 hours ago
- Globe and Mail
Meta Platforms Stock (NASDAQ:META) Slips on New Smart Glasses, AI Logs
The Oakley Meta HSTN glasses—a co-production of social media giant Meta Platforms (META) and EssilorLuxottica—recently emerged, as Meta continues a practice of trying to take on the wearable tech market, which some thought was dead, or sufficiently full to where it no longer mattered. But that, and an unexpected new connection to artificial intelligence, left investors cold. Meta shares slid fractionally in Friday afternoon's trading. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The Oakley Meta HSTN glasses—which I am assured, amazingly, is pronounced how-stun—is the first step beyond the Ray-Ban brand, reports note. The new glasses will draw on the PRIZM Lens technology Oakley is known for, which delivers different responses to various weather conditions and light levels. Plus, the HSTN line has improved battery life over its predecessors as well as a better camera. Plus, the HSTN glasses will pack a connection to the Meta AI digital assistant, which allows for a range of functions, starting with recording videos on command or retrieving weather data. The HSTN glasses are water resistant—which means they cannot be immersed to a specific depth, but will do just fine against rain and sweat—and offer several frame color choices for aesthetics. There is even a 'limited-edition' version that offers gold lenses, but will cost $499. Be Careful What You Ask That AI But then, a more disturbing revelation emerged about Meta and its connection to AI. Meta's AI system as a tab known as 'Discover,' which apparently keeps track of what people ask Meta. And then, reveals that to other people. That is all fine and well when you want Meta AI to make you a picture of an '…adorable Maltese dog (that) becomes a heroic lifeguard,' but if you're like one guy who asked about countries were '…younger women like older white men,' it may not be the kind of thing you want known. And the discussion topics get worse and weirder from there; don't ask about the poor Nigerian fellow who developed a rash somewhere on his person after shaving. The list goes on; Specific medical issues are discussed, discussion on crimes committed, extramarital affairs, and even specific home addresses are given. And this is leading to a growing number of users calling for the Discover tag to be removed. While text prompts were apparently pulled for a while, subsequent reports noted they returned later. Is Meta Platforms a Buy, Sell or Hold? Turning to Wall Street, analysts have a Strong Buy consensus rating on META stock based on 42 Buys, three Holds, and one Sell assigned in the past three months, as indicated by the graphic below. After a 40.62% rally in its share price over the past year, the average META price target of $707.16 per share implies 2.59% upside potential. See more META analyst ratings Disclosure
